FCN 342
Alternative Names: FCN-342Latest Information Update: 10 Oct 2022
At a glance
- Originator Shanghai Fosun Pharmaceutical
- Class Antigouts; Small molecules
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout
Most Recent Events
- 06 Oct 2022 Phase-II clinical trials in Gout in China (unspecified route) prior to October 2022 (Shanghai Fosun Pharmaceutical pipeline, October 2022)
- 05 Oct 2022 Phase-I clinical trials in Gout in China (unspecified route) prior to October 2022 (Shanghai Fosun Pharmaceutical pipeline, October 2022)
- 04 Oct 2022 Preclinical trials in Gout in China (unspecified route) prior to October 2022 (Shanghai Fosun Pharmaceutical pipeline, October 2022)